To examine whether KCa3.1 blockade is able to reverse established diabetic nephropathy, an eNOS-/- mouse model of diabetic nephropathy was established as previously described [11] and then treated with the selective pharmacological inhibitor of KCa3.1, TRAM34 [26]. This evidence concerns the gene KCNN4 and diabetic kidney disease.